Admissions:
CK Infrastructure Holdings (CKI.L) joined the Main Market on 19 August, as the first corporate to list on the International Commercial Companies Secondary Listing Category, a new segment of the LSE.
MOH Nippon (MOH.L) (formerly Bowen Fintech plc) rejoined the Official List (Equity Shares (transition) category) and to trading on the Main Market of the LSE on 19 August, after a reverse takeover of Minnadeooyasan-Hanbai Co. Ltd. with an opening market capitalisation of approximately £42.7m.
Earnz (EARN.L) rejoined the AIM market on 31 August after the completion of the reverse takeover of two companies in the energy services sector: Cosgrove & Drew Ltd (C&D) and South West Heating Services Ltd (SWHS). The deal size was £2.05m, of which £1.56m is EIS/VCT qualifying.
Delistings:
Fix Price Group (FIXP.L) delisted from AIM on 19 August.
Alpha Financial Markets Consulting (AFM.L) delisted from AIM on 20 August.
Plant Health Care (PHC.L) and Sondrel (SND.L) delisted from AIM on 21 August.
Redrow (RDW.L) delisted from the Main Market on 23rd August after a merger with Barratt Developments plc.
Coro Energy* (Suspended) (CORO.L)
The South East Asian energy company with a natural gas and clean energy portfolio notes the announcement released by Conrad Asia Energy Limited (Conrad), the holder of a 76.5% operated interest in the Duyung Production Sharing Contract (PSC), offshore Indonesia, in which the Group has a 15% interest. Conrad announced today that it has agreed a binding Gas Sales Agreement (GSA) for the sale and purchase of the export portion of natural gas from the Mako gas field with Sembcorp Gas Pte Ltd (Sembcorp) headquartered in Singapore. The contract term of the GSA is until the end of the Duyung PSC in January 2037 and allows for the sale of up is 76 billion British thermal units per day (Bbtud), which is equivalent to around 76.9 million standard cubic feet per day (mmscfd). Meanwhile, Coro Energy confirms that it expects to finalise and publish its Annual Report and unsuspend the shares early in September.
CRISM Therapeutics Corporation 15.5p £5.1m (CRTX.L)
The innovative UK drug delivery company focused on the localised delivery of chemotherapy drugs announces that the Company has been awarded an Innovation Passport from the UK Medicine and Healthcare products Regulatory Agency (MHRA) for its lead programme, ChemoSeed in high grade gliomas. Award of an Innovation Passport is the first step in the MHRA’s Innovative Licensing and Access Pathway (ILAP) programme, which aims to accelerate the development of innovative technologies in areas of unmet medical need by providing access to a broad range of support throughout the product design, development and approvals process. Separately, the Company announces it has received £25,000 in Grant Funding from SPARK The Midlands, a network which aims to bridge the gap between medical research discoveries of novel therapeutics, medical devices and diagnostics and real-world clinical use.
Feedback 56p £7.5m (FDBK.L)
The clinical infrastructure specialist announces that it has secured further funding to extend the delivery of its Community Diagnostic Centre (CDC) pathway pilot at the Northern Care Alliance NHS Foundation Trust (NCA) site in Oldham. Feedback has successfully supported Oldham CDC's application for further pathway funding from the 2024-25 NHS England budget, securing a paid contract extension as outlined in the original pilot announcement, on 21 March 2024. This further funding is for £69,000 with an initial 50% paid from the NHSE H1 budget to 30 September 2024, with the balance expected from the NHSE H2 budget to continue the pilot to 31 March 2025.
MTI Wireless Edge 42p £36.5m (MWE.L)
The technology group focused on comprehensive communication and radio frequency solutions across multiple sectors, announces that MTI Summit has received an order totaling approximately Euro 2.6m, for the delivery of radio frequency components to its biggest customer in the defence sector. The deliveries are expected to be fulfilled by the end of 2025. CEO Moni Borovitz indicates that this order is the result of the success of design wins in recent years and the Company is now benefiting from this customer's success in the international market.
Oncimmune Holdings 20.05p £14.9m (ONC.L)
The leading autoantibody profiling company providing research services to the pharmaceutical and biotechnology industry to enable the delivery of precision medicine announces another new contract win with a Top 10 Global Pharma Company. Further to its announcement on 9 August 2024 of an agreement for a new contract with a major global pharmaceutical company with a value of at least US$1.5m, Oncimmune has now agreed a new project with another major pharmaceutical company, with the contract value of US$0.7m. The contract is with a customer for whom Oncimmune is already a preferred supplier under a long-term master services agreement. The Company is in a strong position to meet its targets for FY24 and reach profitability in FY25.
Sareum Holdings* 29.5p £31.8m (SAR.L)
The clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer announces that it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent on SDC-1801, a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases. Sareum has now secured patent coverage in the major territories, following patent approvals by the European Patent Office, China National Intellectual Property Administration and Japan Patent Office for the same protections. The Company expects the US patent to be granted by the end of 2024, subject to the fulfilment of certain formalities with the USPTO.
SRT Marine Systems 28.5p £63.5m (SRT.L)
The global provider of maritime domain awareness systems and technologies for security, safety and environmental protection, announces that it has entered two follow-on contracts with two existing sovereign agency customers in Asia worth a total of US$4.6m over the next 12 months. The Contracts cover a 12 month period and provide for the maintenance and support of their current SRT-MDA systems. They include the provision of various support, data and maintenance services, with one of the contracts including some existing functionality refinements.
Vertu Motors 69.55p £229.6m (VTU.L)
The leading UK automotive retailer with a network of 192 sales and aftersales outlets announces a trading update with regards to the five-month period to 31 July 2024. Full year FY25 adjusted profit before tax is expected to be broadly in-line with current market consensus. H1 profits will be lower than prior year levels as anticipated. Performance in H2 is expected to improve over prior year levels due to a stronger used car market and enhanced used vehicle trade values; with like-for-like volume growth of 5.0% and the UK used vehicle values are stable on an increasingly constrained supply. The Group's balance sheet remains below target gearing levels.
XP Factory 14.25p £25.0m (XPF.L)
The UK-based pre-eminent experiential leisure company announces its audited final results for the 15 months ended 31 March 2024. Group revenue for the 15 month period increased to £57.3m (12 months 2022: £22.8m), demonstrating the significant growth in scale. Adjusted EBITDA rose to £9.9m (12 months 2022: 4.0m). The cash balance was £3.9m at 31 March 2024 (31 Dec 2022: £3.2m). Trading since the start of the financial year to March 2025 has been positive, with both brands delivering positive volume-driven like-for-like growth, 1.9% in the case of Escape Hunt, and 1.5% in the case of Boom in the 20 weeks to 18 August 2024.
Zenova Group 1.2p £1.7m (ZED.L)
The innovative fire suppression and interdiction solutions company announces an initial order for 920 litres of Zenova FP intumescent / fire retardant paint from a large private trading firm, The Kastrati Group, in Albania. This initial sale has been successfully negotiated by AED Ltd, the Company’s recently announced Albanian sub-distributor, and is separate from the order the Group announced with AED back in July. Revenues will be recognised in this financial year. The basic Zenova FP colour will be customised by the Company to this new, large client's specific tinting needs and then used as a trial application, which is expected to lead to larger follow-on orders.
.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
